Laura Clague
CIK 1388773 · Chief Financial Officer · last filed 2023-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.56M
Companies
7
Total Filings
60
Lifetime Open-Market Net
-$2.03M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LAB | Director | 104,791 | $0.79 | $83.3K | $0 | 2 | 2023-06-16 |
| TVTX | Chief Financial Officer | 35,655 | $55.91 | $1.99M | -$972.2K | 12 | 2022-05-12 |
| GNSS | Director | 286,311 | $1.69 | $483.9K | -$83.5K | 6 | 2022-04-27 |
| STANDARD BIOTOOLS INC. (FLDM) Delisted | Director | 47,501 | $3.71 | $176.2K | $0 | 5 | 2021-05-27 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Chief Financial Officer | 19,473 | — | — | -$955.7K | 21 | 2020-11-17 |
| Genasys Inc. (LRAD) Delisted | Director | 97,600 | — | — | -$14.5K | 11 | 2019-03-20 |
| Genasys Inc. (ATCO) Delisted | Director | 1,000 | $15.48 | $15.5K | $870 | 3 | 2008-12-15 |
Recent Filings · Page 5 of 6
60 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-11-16 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −7,500 | -$180.1K | EDGAR |
| 2018-11-14 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +7,500 | $0 | EDGAR |
| 2018-11-01 | STANDARD BIOTOOLS INC. (FLDM) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2018-05-14 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2018-03-21 | Genasys Inc. (LRAD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-03-16 | Genasys Inc. (LRAD) Delisted | Exer (M) | +25,000 | $0 | EDGAR |
| 2018-02-12 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +2,033 | $0 | EDGAR |
| 2017-05-19 | Genasys Inc. (LRAD) Delisted | Exer (M) | +25,000 | $0 | EDGAR |
| 2017-05-18 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-03-16 | Genasys Inc. (LRAD) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.